Allocetra
Phase 2Small molecule
Allocetra is one of 86 small molecule programs targeting Knee Osteoarthritis. It is currently in Phase 2.
3
Indications
4
Total Trials
4
Active Trials
85
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
143 competitors in Osteoarthritis
#DrugCompanyPhaseTrials
1Allocetra
EEnlivex Therapeutics Ltd.
Phase 2
Toradol
RochePreclinical
Cataflam
NovartisPreclinical
Bayer Aspirin
BayerPreclinical
Enbrel
IImmunex
Preclinical
Glucophage
EMD SeronoPreclinical
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Preclinical
Protonix
WWyeth-Lederle Vaccines
Preclinical
Catapres
Boehringer IngelheimPreclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Osteoarthritis2 trials
Intra-articular Allocetra in Osteoarthritis of the of the Temporomandibular Joint (TMJ)
Recruiting·—·Phase 1·NCT06748651·6 enrolled
Psoriatic Arthritis1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Allocetra. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- EEnlivex Therapeutics Ltd.